+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 19Years +
All Genders
ID07374679

Long-Term Follow-up Study of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell Treatment in Adults With Rotator Cuff Disease

Led by Seoul National University Hospital · Updated on 2026-05-22

21

Participants Needed

1

Research Sites

35 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the long-term safety and effectiveness of allogenic umbilical cord-derived mesenchymal stem cells in patients with rotator cuff disease. The study focuses on monitoring outcomes decades after initial treatment to understand the lasting impact of this therapy. Participants are those who previously received this investigational stem cell treatment in an earlier phase 12a trial. This open-label, single-center study involves a long-term follow-up period extending up to 60 months where patients are observed and evaluated without additional new treatments being administered. During the follow-up, researchers will assess shoulder pain and disability using the Shoulder Pain and Disability Index SPADI score and other measures like the Constant-Murley score and Visual Analog Scale pain during motion. Imaging tests such as MRI will monitor changes in rotator cuff tear size, and any adverse events will be recorded. Participation involves periodic assessments over a five-year period ending in 2032, with safety and efficacy carefully tracked.

CONDITIONS

Brief Title

Long-Term Follow-up Study to Evaluate Long-Term Safety and Efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell in Patients With Rotator Cuff Disease

Research Team

K

KeeJeong Bae, Principal Investigator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here